Biostar Microtech International Corp (2399) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Biostar Microtech International Corp stock TWD 6.83, price TWD 39.65, that is 82.8% below the price, quality 51 out of 100. Rating: strongly overvalued. Calculated from audited financials with 8 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 11.20 TWD – 55.00 TWD · fair‑value band 6.34 TWD – 7.52 TWD · the 39.65 TWD price screens above the 6.83 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.
Follow Biostar Microtech International in your weekly email
Every Wednesday you see whether Biostar Microtech International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Biostar Microtech International Corp. engages in the design, development, manufacture, and marketing of various networking solutions in Taiwan and internationally.
Show moreShow less
The company provides edge computing, industrial automation, EV chargers, digital signage, POS and KIOSK systems, PC (MB/VGA), AI workstations, and human-machine interface solutions. It also offers industrial PCs, motherboards, graphics cards, SSDs, memory, desktop PCs, peripherals, and accessories.
In addition, the company provides electronic technology consulting services; and motherboard, industrial computer, and graphics cards. Its products are used in gaming, creator, home, office, and education applications.
Biostar Microtech International Corp. was founded in 1979 and is based in New Taipei City, Taiwan.
Stock analysis
Biostar Microtech International Corp (2399) currently trades at 39.65 TWD, while our model-based Fair Value estimate is 6.83 TWD, 83% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 9.61 TWD per share, and 0 of the 8 models we run sit above the 39.65 TWD price.
Bear case: the Earnings-Based group reads lowest at 1.22 TWD, and 8 of the 8 models stay below the price. Data coverage for this calculation is low.
Scenario range: 6.34 TWD (bear) to 7.52 TWD (bull), the price of 39.65 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Technology sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Biostar Microtech International Corp reported revenue of 1.7B TWD in FY2025 versus 2.8B TWD in FY2021, a compound −11.1%/yr. Reported net income was 26.2M TWD in FY2025, compounding −48.1%/yr from FY2021.
Key figures
Market cap 7.1B TWD (≈ $217M) Micro · P/E ratio 10.1 · P/S ratio 4.08 · EPS (TTM) 3.93 TWD · Net margin 40.5% · Return on equity 28.6% · Return on assets (EBIT) −0.5% (5-year average) · Operating margin −15.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (medium confidence).
What moves the price
The share trades about 28% below its 52-week high and 93% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Technology peers we cover trades at −6% fair-value upside, at −83%, 2399 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (1.22 TWD to 15.52 TWD). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear6.34 TWDFair Value 6.83 TWDBull7.52 TWD
Price 39.65 TWD · Downside -82.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (3.37 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−14.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.8%
Start year 2020 (pandemic). Over 10 years: −4.8% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−38.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−38.8%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−1% → −9%
2025 sits 175% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
⚠ Revenue per share shrinking 6.9%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Biostar Microtech International Corp with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Computer Hardware · 213 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score51 · Above median
Fair Value upside−82.8% · Bottom 25%
Profitability
Return on equity (12 months)28.6% · Top 25%
Return on assets1.0% · Below median
Net margin (12 months)40.5% · Top 25%
Operating margin (12 months)−15.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)16.8% · Above median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Computer Hardware median · lower = cheaper
P/E (12 months)10.1× · Cheapest 25%
P/B3.24× · Pricier than median
P/S (12 months)4.08× · Priciest 25%
PEG0.28× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 8
FUTURE (revenue growth)84· sector 84
PAST (return on equity)100· sector 33
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 50
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Biostar Microtech International Corp Fair Value". https://www.fairvalue-calculator.com/stock/2399
Frequently asked questions
Is Biostar Microtech International Corp (2399) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 6.83 TWD versus a price of 39.65 TWD, about 83% lower (overvalued).
What is the fair value of 2399?
Our model-based fair value for Biostar Microtech International Corp is 6.83 TWD (as of Nov 7, 2026), built from audited fundamentals. The current price: 39.65 TWD.
What is the quality score of 2399?
Biostar Microtech International Corp has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biostar Microtech International Corp (2399)?
Our model-based price target is the fair value of 6.83 TWD (as of Nov 7, 2026) from 8 valuation models. Cautious scenario 6.34 TWD, optimistic scenario 7.52 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Biostar Microtech International Corp stock forecast for 2026?
Our models put fair value at 6.83 TWD, about 83% lower versus a price of 39.65 TWD (overvalued). Cautious scenario 6.34 TWD, optimistic scenario 7.52 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Biostar Microtech International Corp (2399)?
Biostar Microtech International Corp reported trailing-twelve-month revenue of about 1.7B TWD (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Biostar Microtech International Corp (2399)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biostar Microtech International Corp it is 6.83 TWD per share (as of Nov 7, 2026), against a price of 39.65 TWD. It is the blended result of 8 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Biostar Microtech International Corp stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 2399 trades above its calculated fair value: price 39.65 TWD, fair value 6.83 TWD, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2399?
No. The price is what the market pays today (39.65 TWD); the fair value is what the company's own numbers justify (6.83 TWD). For Biostar Microtech International Corp the two are 32.82 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Biostar Microtech International Corp worth?
The market values Biostar Microtech International Corp at about 7.1B TWD (market capitalisation, as of Nov 7, 2026). Per share that is 39.65 TWD; our models calculate a fair value of 6.83 TWD per share.
What do the bullish and bearish scenarios say about 2399?
Our models span a range for Biostar Microtech International Corp: cautious scenario 6.34 TWD, base 6.83 TWD, optimistic 7.52 TWD per share (as of Nov 7, 2026, price 39.65 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2399?
Biostar Microtech International Corp trades at a price-to-earnings ratio of 10.1 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 6.83 TWD is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2017 to 2025), reported earnings: 174.3. Other multiples: PEG 0.3, P/B 3.2, P/S 4.1.
What is the PEG ratio of 2399?
The PEG ratio of Biostar Microtech International Corp is 0.28 (P/E divided by earnings growth, as of Nov 7, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Biostar Microtech International Corp (2399)?
Balance-sheet figures for Biostar Microtech International Corp (as of Nov 7, 2026): return on equity 28.6%, debt of 0.00 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 2399 from its 52-week high?
Biostar Microtech International Corp trades at 39.65 TWD, about 28% below its 52-week high of 55.00 TWD and 93% above the low of 20.55 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 6.83 TWD is for.
Which stocks are comparable to Biostar Microtech International Corp?
From the same area (Technology) we also value Dell Technologies Inc, Arista Networks, Inc, Sandisk Corporation, Seagate Technology Holdings, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biostar Microtech International Corp stock attractive at the current price?
The data as of Nov 7, 2026: price 39.65 TWD, calculated fair value 6.83 TWD (−83%), Quality Score 51/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2399 calculated?
We run Biostar Microtech International Corp through 8 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 6.83 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Biostar Microtech International Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biostar Microtech International Corp (2399)?
The closing price on Nov 9, 2026 was 39.65 TWD. Our model-based fair value is 6.83 TWD, about 83% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biostar Microtech International Corp right now?
The price sits above even our optimistic bull case (7.52 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Biostar Microtech International Corp
How large is the market capitalisation of Biostar Microtech International Corp (2399)?
The market capitalisation of Biostar Microtech International Corp is 7.1B TWD (≈ $217M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biostar Microtech International Corp (2399)?
The price-to-sales ratio of Biostar Microtech International Corp is 4.08 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biostar Microtech International Corp (2399)?
Earnings per share at Biostar Microtech International Corp are 3.93 TWD (price ÷ EPS = P/E 10.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Biostar Microtech International Corp (2399)?
The net margin of Biostar Microtech International Corp is 40.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biostar Microtech International Corp (2399)?
The return on equity (ROE) of Biostar Microtech International Corp is 28.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biostar Microtech International Corp (2399)?
On an EBIT basis the return on assets of Biostar Microtech International Corp is −0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biostar Microtech International Corp (2399)?
The operating margin of Biostar Microtech International Corp is −15.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biostar Microtech International Corp (2399)?
Revenue at Biostar Microtech International Corp is growing +16.8% versus a year earlier (3y avg −8.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biostar Microtech International Corp (2399)?
Earnings per share at Biostar Microtech International Corp are growing +23.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Biostar Microtech International Corp (2399) generate?
The free cash flow of Biostar Microtech International Corp is −96.4M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Biostar Microtech International Corp (2399) hold?
Biostar Microtech International Corp holds more cash than debt, 835M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Biostar Microtech International Corp in the live analysis
One click puts Biostar Microtech International Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026